H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Cuts Target Price to $20
TransCode Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
TransCode Therapeutics Analyst Ratings
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment Efficacy
TransCode Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. : The TransCode Therapeutics (RNAZ.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $3.00.
TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Mustang Bio (MBIO), TransCode Therapeutics (RNAZ)
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Nyxoah (NYXH)
TransCode Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Alpine Immune Sciences (ALPN) and TransCode Therapeutics (RNAZ)
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
TransCode Therapeutics Analyst Ratings
Promising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily Bodnar
TransCode Therapeutics Analyst Ratings
No Data